Please login to the form below

Not currently logged in
Email:
Password:

mergers and acquisitions

This page shows the latest mergers and acquisitions news and features for those working in and with pharma, biotech and healthcare.

BMS defends Celgene buyout ahead of shareholder vote

BMS defends Celgene buyout ahead of shareholder vote

CEO Giovanni Caforio and the BMS board are unanimous - but have a nailbiting vote ahead. ... However Starboard Value has today produced its own updated presentation deck, arguing that previous mega-mergers have not gone well, and warning that BMS could

Latest news

  • Merck & Co to buy IO specialists Immune Design for $300m Merck & Co to buy IO specialists Immune Design for $300m

    Big pharma, biotech and academia are zeroing in on a range of immune system mechanisms which could prove crucial to fighting diverse diseases. ... Merck has a rich history of discovery and innovation and a strong track record of developing meaningful

  • Pfizer takeover rumour ignites Amarin shares Pfizer takeover rumour ignites Amarin shares

    which found that the drug cut the risk of heart attacks and stroke by 25% in high-risk cardiovascular patients. ... Smaller acquisitions could well be on the cards however, with Bourla suggesting that Pfizer will be “aggressive” in business

  • Lilly adds to pharma M&A run with $8bn Loxo buy-out Lilly adds to pharma M&A run with $8bn Loxo buy-out

    Loxo also has a promising pipeline, which includes LOXO-292, an oral RET inhibitor being studied across multiple tumour types,   and which was recently granted FDA Breakthrough Therapy designation,   and could ... Gilead, Amgen and Biogen are among

  • BMS and Celgene deal sparks debate on pharma profit motive, more M&A BMS and Celgene deal sparks debate on pharma profit motive, more M&A

    Mergers that mean more money for drug company CEOs while patients pay the price are not a solution to skyrocketing drug costs,” she said. ... Two companies mentioned as potential likely buyers in the market are AbbVie and Merck &Co.

  • BMS and Celgene announce $74bn merger BMS and Celgene announce $74bn merger

    the sheer scale and likely impact for competitors is huge news for the sector. ... It also TYK2 and ozanimod in immunology and inflammation, and two more in haematology: luspatercept and fedratinib.

More from news
Approximately 17 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Mergers and acquisitions - still waiting for the tax-driven wave of activity. ... manufacture and supply of Kymriah. $40m. Development. collaboration. Pfizer. Novartis to develop combination.

  • Change in the pharma industry is inevitable Change in the pharma industry is inevitable

    A high proportion (88%) of change initiatives fail. A similar proportion of business strategies, mergers and acquisitions suffer the same fate. ... However, the bad news is that countless research has clearly demonstrated that only 10-30% of mergers or

  • Deal Watch March 2017 Deal Watch March 2017

    By contrast, as well as five company acquisitions, there are a couple of product acquisitions in our Top 20, which might start to explain where the licences are going. ... Among the company acquisitions, Sartorius paid $320m in cash to acquire the

  • Deal Watch February 2017 Deal Watch February 2017

    Such a shareholder revolt seems more akin to what we have seen previously for company acquisitions rather than for a licensing transaction. ... Future deals to look out for? Looking ahead there are likely to be some further significant acquisitions in

  • Deal Watch January 2017 Deal Watch January 2017

    Actelion, Johnson &Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up. ... 250. Vertex. Merck KGaA. Collaboration. VX 970 VX 803 and 2 others ATR inhibitors.

More from intelligence
Approximately 12 fully matching, plus 59 partially matching documents found.

Latest appointments

  • New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics

    Latest movers in pharma. Mundipharma hires new SVP business development and strategic partnerships. ... Cerato brings with him a wealth of business development experience, including in-licensing, out-licensing, alliance management, and mergers and

  • Ipsen bolsters leadership team Ipsen bolsters leadership team

    acquisition of drug candidates, commercial products and companies for the global speciality drug business. ... With expertise in corporate partnering, mergers and acquisitions, pipeline and product portfolio development, legal and IP strategy,

  • IRX Therapeutics appoints Luba Greenwood to its board IRX Therapeutics appoints Luba Greenwood to its board

    Her career has spanned leadership roles in venture investing, business development, mergers and acquisitions, law, consulting and operations. ... Prior to that, she served as senior mergers and acquisitions counsel at Pfizer.

  • Apeiron bolsters management board Apeiron bolsters management board

    With more than 25 years’ experience in initial public offerings, mergers and acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, Llewellyn-Davies most recently ... During the course of his career

  • Sobi appoints Torbjorn Hallberg as general counsel Sobi appoints Torbjorn Hallberg as general counsel

    He arrives at Sobi will more than 15 years’ experience covering licensing, mergers and acquisitions at pharma groups such as  Ferring and Nycomed. ... Carin Dahlquist (an acting role), head of EMENA Hege Hellström and head of North America Rami Levin.

More from appointments
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics